trending Market Intelligence /marketintelligence/en/news-insights/trending/id_lfps7acexjvttkhuzxg2 content esgSubNav
In This List

Sun Pharmaceutical skin drug bags US FDA approval

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Sun Pharmaceutical skin drug bags US FDA approval

India's Sun Pharmaceutical Industries Ltd. secured the U.S. Food and Drug Administration's approval to market Ilumya as a treatment for moderate-to-severe plaque psoriasis.

Plaque psoriasis is a skin disease that causes red, painful and itchy patches with a silvery white buildup of dead skin cells or scale.

The company's regulatory filing was backed by the results of two phase 3 clinical trials that demonstrated the treatment was better at improving skin clearance than placebo.